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Myeloid cells play a critical role in perpetuating inflammation
during various chronic diseases. Recently the death of macro-
phages through programmed necrosis (necroptosis) has emerged
as an important mechanism in inflammation and pathology. We
evaluated the mechanisms that lead to the induction of necrotic
cell death in macrophages. Our results indicate that type I IFN (IFN-I)
signaling is a predominant mechanism of necroptosis, because
macrophages deficient in IFN-α receptor type I (IFNAR1) are highly
resistant to necroptosis after stimulation with LPS, polyinosinic-
polycytidylic acid, TNF-α, or IFN-β in the presence of caspase
inhibitors. IFN-I–induced necroptosis occurred through both
mechanisms dependent on and independent of Toll/IL-1 receptor
domain-containing adaptor inducing IFN-β (TRIF) and led to persis-
tent phosphorylation of receptor-interacting protein 3 (Rip3) kinase,
which resulted in potent necroptosis. Although various IFN-regu-
latory factors (IRFs) facilitated the induction of necroptosis in re-
sponse to IFN−β, IRF-9–STAT1– or -STAT2–deficient macrophages
were highly resistant to necroptosis. Our results indicate that IFN-
β–induced necroptosis of macrophages proceeds through tonic
IFN-stimulated gene factor 3 (ISGF3) signaling, which leads to per-
sistent expression of STAT1, STAT2, and IRF9. Induction of IFNAR1/
Rip3–dependent necroptosis also resulted in potent inflammatory
pathology in vivo. These results reveal how IFN-I mediates acute
inflammation through macrophage necroptosis.
Innate immune cells, such as macrophages, serve as one of thefirst lines of defense against invading pathogens. Upon rec-
ognition of pathogen-associated molecular patterns (PAMPs)
such as bacterial LPS, macrophages are activated to initiate in-
flammation through the release of cytokines (1). Recently it has
been demonstrated that, when combined with caspase inhibition,
LPS also can initiate a form of programmed necrotic cell death
(necroptosis) that is dependent on signaling through the re-
ceptor-interacting proteins 1 and 3 (Rip1 and Rip3) (2). These
results add to the number of cell-stress pathways shown to
stimulate necroptotic signaling, including cell death receptor
signaling (3), secondary mitochondria-derived activator of cas-
pases mimetics (4), viral infection (5), and genotoxic stress (6).
Recent work has demonstrated convincingly that activation of
the Rip1 and Rip3 kinases is associated with the release of potent
inflammatory cytokines even in the absence of cell death (7, 8).
Consistent with this association, necrostatin-1, an inhibitor of
Rip1 kinase activity, has been demonstrated to block Rip1-
dependent activation of TNF-α production (9). Downstream of
necrotic cell death, the release of intracellular damage-associ-
ated molecular patterns (DAMPs) into the extracellular envi-
ronment has been thought to promote the inflammatory
phenotype associated with this form of cell death (10). Various
reports have demonstrated that deficiency in necroptosis sig-
naling in vivo leads to less inflammatory pathology in mouse
models of systemic inflammatory shock (11–13).
Macrophages recognize PAMPs through Toll-like receptors
(TLRs). The LPS receptor TLR4 activates two distinct signaling
axes: the myeloid differentiation response gene-88 dependent
pathway (Myd88), which leads to NF-κB activation (14), and
the Toll/interleukin-1 receptor domain-containing adapter-
inducing IFN-β (TRIF) dependent pathway, which leads to the
production of type I interferons (IFN-I) (15). Recently TRIF also
has been directly implicated in the induction of necroptotic sig-
naling (2, 16). The IFN-I receptor is composed of a heterodimer
of the two IFN-α receptor type I proteins (IFNAR1 and
IFNAR2). Binding of IFN-I (IFN-α or IFN-β) to the ubiquitous
IFN-I receptor (IFNAR1) activates several signaling pathways,
including JAK/STAT, NF-κB, and PI3K (17). The best-studied
IFN-I signaling pathway involves the activation of the Janus
kinases JAK1 and Tyk2, which in turn activate STAT1 and induce
an antiviral state within the cell. STAT1 activates the expression
of genes which encode proteins such as protein kinase R (PKR),
which shuts down protein translation, and IFN-regulatory factor 9
(IRF9), which further modifies the gene response to IFN (18). In
the presence of IRF9 expression, IFN signaling leads to the for-
mation of the STAT1/STAT2/IRF9 complex known as “ISGF3,”
which acts as a powerful antiviral regulatory complex within the
cell (19). Given the wide clinical relevance of IFN-I in conditions
ranging from hepatitis C infection (20), to cancer (21), multiple
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sclerosis (22), atherosclerosis (23), and diabetes (24), novel in-
sight into mechanisms of IFN-I is highly relevant to the un-
derstanding and treatment of these diseases.
In this paper we provide evidence that IFN-I signaling is
necessary for sustained Rip3 activation and the induction of
necroptosis after LPS, polyinosinic-polycytidylic acid (polyI:C),
or TNF-α stimulation of macrophages. Specifically, we show that
ISGF3-dependent IFNAR1 signaling results in sustained acti-
vation of Rip3. Finally, we show that IFN-induced necroptosis
drives systemic inflammatory shock. Thus, we have provided
a mechanism for the central role of IFN-I in necroptosis and
acute inflammatory shock (25–27). The ability of IFN-I to induce
inflammatory necroptosis in innate immune cells represents a par-
adigm shift in the understanding of both necroptosis and IFN-I.
Results
IFN-I Signaling Is Required for LPS-Induced Necroptosis in Macrophages.
Most studies on necroptosis involve evaluation of the signaling
mechanisms in nonimmune cells (28), in which case necroptosis
most commonly is induced by stimulating cells with TNF-α in
the absence of caspase signaling (benzyloxycarbonyl-Val-Ala-Asp-
fluoromethylketone, zVAD-FMK) (29). Our results obtained with
similar experimental protocols indicate that mouse embryonic
fibroblasts undergo necroptosis in response to TNF-α but not
LPS signaling (Fig. 1A). Interestingly, bone marrow-derived
macrophages undergo necroptosis in response to both TNF-α
and LPS in combination with zVAD (Fig. 1A). Cell death was
evaluated relative to respective treatment controls (LPS, IFN-
β, or TNF-α) in the absence of zVAD. When cells were treated
with cytokines or PAMPs alone, no cell death was noticeable
(Fig. S1 A and B). Induction of cell death also was rescued
completely by necrostatin-1 (a specific inhibitor of Rip1 kinase
activity), thus confirming the cell death pathway to be nec-
roptosis (Fig. 1A). We find that this induction of cell death
occurs 8–24 h after treatment (Fig. S1 C and D). Although there
is a dose-dependent increase in necroptosis when zVAD is
combined with LPS, treatment of macrophages with zVAD alone
or with LPS alone does not lead to necroptosis (Fig. 1B). Having
noted that macrophages, unlike fibroblasts, displayed unique sus-
ceptibility to necroptosis in response to LPS, we were interested in
dissecting the mechanism of necroptosis induction in this important
cell type. We also observed that LPS/zVAD-induced cell death of
macrophages was dependent on the expression of Rip3 kinase (Fig.
1C) and was independent of TNF signaling (Fig. 1D). Although
TNF-α is considered to be a canonical inducer of necroptosis (29),
our results indicate that this is not the case for macrophages.
To decipher the mechanism through which LPS signaling in-
duced necroptosis of macrophages, we next examined macro-
phages deficient for key signaling mediators. We observed that
TRIF-deficient macrophages were resistant to zVAD/LPS-
induced death, but Myd88-deficient macrophages were not
protected (Fig. 1E). Because TRIF signaling is involved pri-
marily in the production of IFN-I in response to TLR stimulation
(15), we tested whether IFNAR1 signaling might be important in
the induction of LPS-induced necroptosis. Indeed, we found that
IFNAR1-deficient macrophages were highly resistant to nec-
roptosis induced by LPS/zVAD (Fig. 1 F and G). These results
indicate that IFNAR1 signaling is necessary for the induction of
necroptosis of macrophages after LPS stimulation.
IFNAR1 Signaling Is Vital for Necroptosis Induced by Multiple Pathways
in Macrophages. Similar to our observations in LPS, IFNAR1-
and Rip3-deficient but not TNF receptor 1 (TNFR1)- and
TNFR2-deficient macrophages showed resistance to necroptosis
induction when TLR3 was engaged through polyI:C stimulation
(Fig. 2 A–C). Surprisingly, even with the canonical inducer of
necroptosis, TNF-α, we found that both IFNAR1 and Rip3
expression are needed for induction of necroptotic cell death
(Fig. 2 D–F). Furthermore, IFN-β treatment resulted in nec-
roptosis of TNFR-deficient macrophages (Fig. 2G) but failed
to do so in IFNAR1- or Rip3-deficient macrophages (Fig. 2 G–I).
These results indicate that IFNAR1 signaling, rather than
Fig. 1. IFN-I is required for LPS-induced necroptosis in macrophages. (A) Bone marrow-derived macrophages and mouse embryonic fibroblasts were treated with LPS
(100 ng/mL), TNF-α (50 ng/mL), zVAD (50 μM), and/or necrostatin-1 (30 μM) as shown. After 24 h, cells were examined for viability via theMTT assay. (B–F) Macrophages
generated from bone marrow obtained from various knockout mice were treated for 24 h with various combinations of LPS, zVAD (25–50 μM), and necrostatin-1 (30
μM) and were examined for viability using the MTT assay. Graphs show the percentage of viable cells ± SEM relative to cells treated with the corresponding stimuli in
the absence of zVAD from at least three repeated experiments performed in triplicate. *P < 0.05; **P < 0.001; ***P < 0.0001. (G) Macrophages generated fromWT or
IFNAR1-deficient bone marrow were treated as described above and were examined for viability using Hoechst and propidium iodide costaining.



























TNF-α signaling, is a predominant mechanism of necroptosis
in macrophages. Interestingly, both TRIF- and Myd88-deficient
macrophages showed no resistance to TNF-α– or IFN-β–induced
necroptosis (Fig. 2 J and K). These results emphasize that
necroptosis in macrophages can be induced through diverse
pathways that are always dependent on IFNAR1 signaling.
IFNAR1 Signaling Sustains Prolonged Activation of Rip3. Rip1 and
Rip3 activation (phosphorylation) can be measured via SDS/PAGE
through a shift in migration of these proteins (4, 30). Treatment of
WT macrophages with LPS resulted in phosphorylation of Rip1 but
not Rip3 kinase (Fig. 3A, lane 2). In contrast to Rip1 activation,
LPS induced phosphorylation of Rip3 only when the cells also were
treated with zVAD (Fig. 3A, lane 3). Treatment with zVAD alone
did not result in significant phosphorylation of Rip1 or Rip3 (Fig.
S2A). As expected, necrostatin-1 also was able to block Rip1-
dependent phosphorylation of Rip3 completely but had no effect
on Rip1 phosphorylation (Fig. 3A, lane 4). We also observed that
Fig. 2. IFNAR1 signaling is necessary for poly:I:C-, TNF-, and IFN-I–dependent necroptosis. (A–K) Macrophages generated from bone marrow obtained from
various knockout mice were treated for 24 h with various combinations of LPS, zVAD (25–50 μM), and necrostatin-1 (30 μM) as indicated and examined for
viability using the MTT assay. Graphs show the percentage of viable cells ± SEM relative to cells treated with the corresponding stimuli in the absence of zVAD
from at least three biological replicate experiments performed in duplicate. Statistical analysis was performed only to compare the effect of +zVAD treatment
on different genotypes (gray bars). ***P < 0.0001.
Fig. 3. IFNAR1 signaling sustains prolonged activation of Rip3. (A) Macrophages generated as described in Experimental Procedures were treated for 2 h
with various combinations of LPS, zVAD (50 μM), and necrostatin-1 (30 μM) as shown. Lysates then were examined by Western blot. (B–D) Macrophages
generated from various knockout mouse strains were treated with zVAD (50 μM) and LPS for varying time intervals as shown. Lysates then were examined by
Western blot. (E and F) Densitometry was performed to quantitate the average ratio of pRip1/total Rip1 and pRip3/total Rip3 ± SEM over at least three
separate experiments performed as described above.
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Rip3 phosphorylation occurred later than Rip1 activation, be-
ginning at 2 h and being maintained until at least 6 h posttreat-
ment (Fig. 3B). We confirmed that these slower-migrating forms
of Rip1 and Rip3 were indeed phosphorylated, because treatment
of lysates with lambda phosphatase eliminated the upper bands
(Fig. 3B, Right). We were not able to detect phosphorylation of
mixed lineage kinase domain-like protein (MLKL) using a similar
technique (Fig. S2B). These results indicate that induction of
necroptosis by LPS/zVAD leads to rapid phosphorylation of Rip1
that is followed by delayed activation of Rip3.
At 4 h posttreatment with LPS/zVAD, phosphorylation of
Rip3 was strongly attenuated in TRIF-deficient macrophages, in
contrast to Myd88-deficient and WT macrophages (Fig. 3C).
Longer time courses confirm that phosphorylation of Rip3
occurs between 2 and 6 h posttreatment in WT and Myd88-
deficient cells but is attenuated in TRIF-deficient macrophages
(Fig. S2C). Interestingly, phosphorylation of Rip1 kinase seems
to be slightly delayed in Myd88-deficient macrophages (Fig. 3C
and Fig. S2C). These data suggest that both the Myd88- and
TRIF-dependent pathways may be implicated in the activation of
Rip1 and Rip3 phosphorylation.
As in TRIF-deficient cells, in the absence of IFNAR1 expression
we observed only a transient induction of Rip3 activation after
LPS/zVAD treatment (Fig. 3D). Interestingly, we also saw an IFN-I–
dependent increase in STAT1 phosphorylation coinciding with the
activation of Rip3 kinase (Fig. 3D).This increase in STAT1 and
Rip3 phosphorylation coincided with the induction of IFN-I re-
lease and preceded cell death as defined by loss of plasma mem-
brane integrity (Fig. S1). Densitometric analysis of repeated
Western blots revealed that the ratio of phosphorylated to
unphosphorylated Rip1 was slightly lower in IFNAR1-deficient
macrophages at later time points (Fig. 3E). Analysis also confirms
the more significant differences in Rip3 phosphorylation in WT
and IFNAR1-deficient cells (Fig. 3F). Importantly, densitometric
analysis showed no difference in the loss of total Rip1 during
necroptosis in WT or IFNAR1-deficient macrophages, and we
observed no difference in the induction of Rip1 transcription (Fig.
S2 D and E). These data show that autocrine IFN-I signaling
functions to sustain pronecroptotic Rip1 and Rip3 phosphorylation
long enough to allow the induction of necroptosis.
IRF9 Expression Is Required for Sustained Rip3 Activation and
Necroptosis. A key family of transcription factors, IRFs, pro-
motes the production of IFN and modifies signal transduction
after IFNAR1 engagement. Interestingly, in our model we ob-
served a partial rescue from necroptosis in macrophages lacking
IRF3 but only a minor rescue in those lacking IRF7 (Fig. 4A and
Fig. S3 A and B). In addition we observed a partial rescue in
macrophages deficient in IRF1 (Fig. 4B). Interestingly, IRF1 was
particularly important for TNF-α– but not IFN-β–induced nec-
roptosis (Fig. S3 C and D). Although most IRFs promote the
production of IFN by the host cell, IRF9 plays a unique role in
facilitating the downstream response to IFN-I (19). In contrast to
the partial rescues we observed with IRF1-, IRF3-, and IRF7-
knockout macrophages, IRF9 macrophages were highly resistant
to the induction of necroptosis by LPS, IFN-β, and TNF-α (Fig. 4
C–E). Interestingly, we observed a partial rescue of polyI:C-in-
duced necroptosis in IRF9-deficient macrophages (Fig. 4F). In
our time-course Western blots we also observed a lack of late
Rip3 activation in cells lacking IRF9 expression (Fig. 4 G–I)
similar to that in IFNAR1-deficient cells. Overall these results
indicate that IRFs act redundantly to facilitate the induction of
IFN-I in response to LPS, but IRF9 is specifically required for
the induction of necroptotic cell death.
The ISGF3 Complex Promotes Necroptotic Cell Death. We next were
interested in dissecting the mechanism downstream of IFN sig-
naling that might promote necroptosis of macrophages. Previous
work has suggested that PKR promotes the phosphorylation of
Rip1 and Rip3 (2). In contrast to this result, we find that PKR-
deficient macrophages show no resistance to necroptosis (Fig.
S4A). It should be noted that PKR-deficient macrophages were
generated on a 129SvJ background mouse strain, although we
confirmed a similar requirement of IFNAR1 for necroptosis in
macrophages on a 129 genotype (Fig. S4B). These results indicate
that PKR is not essential for IFN-I–dependent necroptosis
in macrophages.
Given the necroptotic role for IRF9 that we have demonstrated
here and IRF9 mediation of signal transduction through the
ISGF3 complex (31), we hypothesized that IFN-I might mediate
necroptosis specifically through the ISGF3 complex. ISGF3,
Fig. 4. IRF9 expression is required for sustained Rip3 activation and necroptosis. (A–F) Macrophages generated from bone marrow obtained from various
knockout mice were treated for 24 h with various combinations of LPS, zVAD (25–50 μM), and necrostatin-1 (30 μM) and were examined for viability using the
MTT assay. Graphs show the percentage of viable cells ± SEM relative to cells treated with the corresponding stimuli in the absence of zVAD ± SEM from at
least three repeated experiments performed in triplicate. **P < 0.001; ***P < 0.0001. (G) Macrophages derived from the bone marrow of WT or IRF9−/− mice
were treated for varying time intervals with LPS and zVAD as shown. Lysates then were examined via Western blot. (H and I) Densitometry was performed to
quantitate the average ratio of pRip1 to pRip3 over at least three separate experiments performed as described above.



























consisting of a complex of IRF9, STAT1, and STAT2, migrates
to the nucleus to induce transcription of specific target genes
(32). Consistent with a pronecroptotic role for ISGF3, we ob-
served that STAT1-deficient macrophages were partially re-
sistant to necroptosis induced by IFN-β, TNF-α, polyI:C, or LPS
(Fig. 5 A–D). We also observed that macrophages lacking
STAT1 showed reduced Rip3 phosphorylation in response to
LPS/zVAD (Fig. 5E). Similarly, STAT2-deficient macrophages
were resistant to necroptosis induced by IFN-β, TNF-α, polyI:C,
or LPS (Fig. 5 F–I) and showed lower levels of Rip3 phosphor-
ylation after LPS/zVAD treatment (Fig. 5J). These data impli-
cate the key members of the ISGF3 complex—IRF9, STAT1,
and STAT2—in the induction of necroptotic cell death.
Low-level constitutive IFN has been thought to induce tonic
signaling that promotes the activation of STAT1 and STAT2 (32).
Consistent with this notion, we observed that IFNAR1-deficient
macrophages express very low levels of constitutive STAT1 and
STAT2, and these levels remained very low even after stim-
ulation with LPS/zVAD (Fig. 5K). Furthermore, IFNAR1-deficient
macrophages displayed greatly reduced IRF9 transcript levels
with no induction after LPS+zVAD stimulation (Fig. 5L), pin-
pointing ISGF3 as a critical promoter of necroptosis. Stimulation
of WT macrophages with IFN-β alone resulted in a gradual in-
crease in the expression of STAT1 and STAT2, consistent with
the timing of necroptotic cell death (Fig. 5M). Overall these
results support the conclusion that IFN-activated induction of
the ISGF3 complex is required for the activation of necroptosis
within macrophages.
IFN-I–Mediated Necroptosis Drives Inflammatory Pathology in Vivo.
Several recent reports have highlighted the role of IFN-I in acute
systemic inflammation (25, 27, 33); therefore we wanted to in-
vestigate the effects of IFN-I–dependent necroptosis specifically
in vivo. To test the role of IFN-I, we injected WT and IFNAR1-
deficient mice with LPS and zVAD. After an injection of a very
low dose of LPS (2.5 mg/kg) and zVAD (5 mg/kg), IFNAR1-
deficient mice showed a significantly smaller drop in body tem-
perature than WT mice (Fig. 6A). Rip3-knockout mice showed
a similarly reduced response to a low dose of LPS/zVAD in vivo
(Fig. 6A). At a time point when WT mice were almost moribund
(slow movement and hunched posture), IFNAR1-deficient mice
appeared relatively normal (Movie S1).
Next, we examined the inflammatory cytokine levels in mice at
18 h postinjection of LPS/zVAD. In this case, we observed that
IFNAR1-deficient mice showed lower levels of inflammatory
cytokines in their serum (Fig. 6B). We observed a similar trend
of lower cytokine expression in Rip3-deficient mice (Fig. S5). We
also observed that after injection of LPS/zVAD IFNAR1-
deficient mice showed higher numbers of macrophages and sig-
nificantly lower cell death within the macrophage population
(Fig. 6C). These data clearly show that IFN-I signaling is a key
element in the induction of inflammatory necroptosis in vivo.
Finally, we wanted to confirm that differences in the IFN-I–
induced necroptosis pathway could affect mouse survival. After
the injection of a higher dose of LPS/zVAD, mice showed early
signs of distress, including a rapid drop in body temperature. WT
mice reached the humane endpoint of severe pathology and body
temperature below 27 °C within 6–10 h (Fig. 6D). In contrast,
both IFNAR1-deficient and Rip3-deficient mice showed a slower
Fig. 5. The ISGF3 complex promotes necroptotic cell death. (A–D) Macrophages generated from bone marrow obtained from STAT1-knockout and matching
WT mice were treated for 24 h with various combinations of LPS, TNFα, polyI:C, zVAD (50 μM), and necrostatin-1 (30 μM) as shown and were examined for
viability using the MTT assay. (E) Macrophages derived from the bone marrow of WT, STAT1−/−, or IFNAR1−/−mice were treated for varying time intervals with
LPS and zVAD as shown. Lysates then were examined via Western blot. (F–J) Macrophages from STAT2-knockout and WT mice were generated and treated as
described above. Graphs show the percentage of viable cells ± SEM relative to cells treated with the corresponding stimuli in the absence of zVAD from at
least three repeated experiments performed in triplicate. Statistical analysis was performed only to compare the effect of +zVAD treatment on different
genotypes (gray bars). ***P < 0.0001. (K) Macrophages generated fromWT and IFNAR1−/−mice were treated for varying time intervals with LPS and zVAD (50
μM) and were examined for the expression of STAT1 and STAT2 by Western blot. (L) Total RNA for quantitative RT-PCR was extracted fromWT and IFNAR1−/−
bone marrow-derived macrophages after 6 h with or without LPS + zVAD treatment. (M) WT macrophages were cultured with IFN-β (100 U/mL) for various
time intervals, and cell extracts were tested for the expression of STAT1 and STAT2 by Western blotting.
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progression of pathology, and 50–60% of mice remained healthy
beyond 24 h (Fig. 6D). Finally, we examined the drop in body
temperature of mice injected with a lethal dose of LPS in the
absence of zVAD (50 mg/kg). Again we observed a significant
difference between WT and Rip3-deficient or IFNAR1-deficient
mice (Fig. 6E). These data support a model in which IFN-I–
induced necroptosis is a significant driver of inflammatory pa-
thology and may play a key role in acute inflammatory pathology
such as observed in sepsis.
Discussion
The understanding of programmed necrotic cell death has ad-
vanced rapidly in recent years. It is now known that various
immunostimulatory and cell-stress pathways converge to stimu-
late the phosphorylation-induced formation of the Rip1/Rip3
necrosome complex (10, 34). Previously, it was thought that
strong inducers of necroptosis such as TNF-α/zVAD or LPS/
zVAD rely primarily on the direct activation of Rip1 phosphor-
ylation through specific signaling complexes (2, 35). In contrast to
this view, however, our evidence indicates that feedback signaling
through IFNAR1 is necessary for the sustained Rip1 and Rip3
activation which leads to necroptotic cell death (Fig. 7).
Our work establishes that Rip1 kinase is activated quickly in
response to TLR stimulation. For Rip1 activation, we find that
caspase inhibition is irrelevant and serves only to prevent the
later induction of Rip3 phosphorylation. This result adds to
previous work showing that caspase-8 promotes the regulation of
the Rip1/Rip3 necrosome (36, 37). We provide evidence that,
directly downstream of TLR4, macrophages deficient in either
TRIF or Myd88 are capable of activating Rip1 phosphorylation
but show significant differences in the phosphorylation of Rip3.
Specifically, we show, for the first time to our knowledge, that
TRIF acts specifically to induce a longer-lasting activation of
Rip3. In general, our data indicate either that multiple kinases
are likely able to activate Rip1 kinase or that a common pathway
between these diverse receptors must activate Rip1. Further-
more the location, timing, and extent of Rip1 activation are
likely determinants of the activation of Rip3 and downstream
necroptotic cell death machinery.
We demonstrate that IFNAR1 signaling downstream of TRIF
is responsible for the sustained activation of Rip3 kinase. In
addition, we show that IFNAR1-deficient macrophages are re-
sistant to TNF-α/zVAD–induced necroptosis, a surprising finding
given that TNFR signaling has been studied so extensively as a di-
rect activator of Rip1-dependent death (3). Consistent with such
Fig. 6. In vivo injection of LPS/zVAD leads to IFNAR1/Rip3-dependent necroptosis and inflammatory pathology. (A) (Left) WT, IFNAR1−/−, and Rip3−/− mice
were injected with a low dose of LPS (2.5 mg/kg) and zVAD (5 mg/kg) and were monitored for a drop in body temperature. (Right) Spread of body tem-
perature at 6 h postinjection (n = 5 mice per group). (B) WT and IFNAR1−/−mice were challenged with a higher dose of LPS (5 mg/kg) and zVAD (5 mg/kg) and
were killed at 18 h postinjection. Serum was drawn by cardiac puncture and was examined for cytokine levels via ELISA array (n = 3 mice per group). (C) After
cardiac puncture, peritoneal lavage was performed and examined via flow cytometric analysis (n = 3 mice per group). (D) WT, IFNAR1−/−, and Rip3−/− mice
were challenged with a lethal dose of LPS (10 mg/kg) and zVAD (5 mg/kg) and were examined for survival over 24 h (n = 8 WT and 5 IFNAR1/Rip3 genotypes).
(E) WT, IFNAR1−/−, and Rip3−/−mice were challenged with a lethal dose of LPS alone (50 mg/kg) and were examined for body temperature 6 h after challenge
(n = 3 mice per group). All graphs show mean measurements ± SEM. *P < 0.05; **P < 0.001;***P < 0.0001.
Fig. 7. Model of the role of IFN-I signaling as a key inducer of necroptosis. A
number of cell-surface receptors lead to the activation of autocrine IFNAR1
signaling through redundant IRF family members. IFNAR1 signaling even-
tually leads to the assembly and activation of the ISGF3 complex, which in
turn promotes sustained activation of the Rip1/Rip3 necrosome complex.
Ultimately sustained necrosome activation leads to the induction of nec-
roptotic cell death and release of inflammatory DAMPs.



























a view, work has shown that IFNAR1-deficient mice are resistant to
TNF-α–induced shock in vivo (27). Consistent with our observa-
tions, this pathway of TNF-α–induced IFN-β expression has been
demonstrated to occur through an IRF-1–dependent mechanism
(38) and appears to occur within endothelial cells as well as mac-
rophages (39). Underlining the importance of IFNAR1, we also
have observed that LPS- or polyI:C-induced necroptosis of macro-
phages is unaffected by the lack of TNFR1/2 but is highly de-
pendent on IFNAR1 expression. Our results add IFN-I to a growing
list of cellular signaling mechanisms, including multiple TLRs,
death receptors, and cell stress pathways, known to activate Rip1
kinase (34, 40). Furthermore, our data show that, although TNFR
expression is not specifically required for necroptosis to occur, IFN-I
signaling appears to be required for necroptosis in macrophages.
To elucidate how IFNAR1 is able to support a sustained
activation of the Rip1/Rip3 necrosome, we also examined
a number of additional deficient mice. Consistent with previous
understanding of IRFs (41), we found evidence of redundancy in
the role of various IRFs in activating the expression and release
of IFN-I in response to TLR stimulation. In contrast to our
observations in other IRFs, IRF9-deficient macrophages phe-
nocopied IFNAR1-deficient cells, exhibiting little necroptotic
cell death in response to LPS, IFN-β, or TNF-α. In addition to
IRF9, we find that STAT1- or STAT2-deficient macrophages are
partially resistant to necroptosis, supporting a view that ISGF3 is
required for late activation of Rip3 kinase. In contrast to pre-
vious work (42), we have excluded a role for PKR in the induction
of IFNAR1-dependent necroptosis. Further work will be neces-
sary to elucidate the exact mechanism by which IRF9/ISGF3
sustains the activation of Rip3 at later time points, but here we
add to recent work showing that IRF9 specifically mediates the
antiproliferative and proapoptotic effects of IFN-α (43).
The importance of necroptosis to the inflammatory program in
vivo has become an intensive area of study in recent years. Studies
have demonstrated that deficiency in Rip1/Rip3 signaling in vivo
leads to less inflammatory pathology in various mouse models of
systemic inflammatory shock (11–13). Similarly, work has directly
implicated IFN-I signaling in systemic shock (25, 27). Despite the
extensive use of zVAD as an inducer of necroptosis in vitro (28),
only recently has it has been used as a means of investigating nec-
roptosis in vivo (2). In our in vivo model, we used a combination of
zVAD and LPS to study the effects of necroptotic cell death in vivo.
Our results provide a mechanism by which IFN-I drives Rip3-
dependent necroptotic cell death and in turn can drive inflammation
through the release of inflammatory DAMPs such as high-mobility
group box-1 (HMGB1) protein (10). Consistent with this proposed
mechanism, elevated serum levels of HMGB1 are commonly seen
in patients undergoing septic shock (44), and the blocking of
HMGB1 is being pursued for therapeutic purposes (45).
In summary, the data presented in this article show that IFN-I
signaling drives the sustained activation of the Rip1/Rip3 necrosome
necessary for necroptosis of innate immune cells that ulti-
mately leads to inflammatory pathology. This finding may il-
luminate new therapeutic avenues to intervene in cases of
acute inflammatory pathology such as sepsis.
Experimental Procedures
Animal Work. Animals were maintained in accordance with Canadian Council
on Animal Care guidelines. Protocols and procedures were approved and
monitored by the National Research Council of Canada-Institute for Bi-
ological Sciences Animal Care and Ethics Board and/or the University of
Ottawa Animal Care Committee. Strains of mice used for experiments are as
follows: WT C57BL6/J (Jax #000664), TRIF−/− (Jax #005037), Myd88−/− (Jax
#009088), TNFR1/2−/− (Jax #003243), IFNAR1−/− (a kind gift from Kaja Murali-
Krishna, Emory University, Atlanta), and PKR-knockout mice and matched
controls (obtained from John Bell, Ottawa Hospital Research Institute Ot-
tawa) were on the 129SvEv background (46). STAT1−/− mice (Taconic 2045-F)
and matched WT controls (Taconic 129SVE-F) were obtained from Taconic.
STAT2−/− mice were generated by crossing 129SvJ/Stat2−/− mice (a kind gift
from Christian Schindler, Columbia University, New York) onto the C57/BL6
background for 11 generations. Rip3−/− mice were a kind gift from Vishva
Dixit (Genentech, San Francisco). IRF3−/− mice were generated as described
in ref. 47; IRF7−/− mice were generated as described in ref. 19; IRF9−/− mice
were generated as described in ref. 48; and IRF3/7−/−mice were generated as
described in ref. 49. Genetic analysis necessary for strain determination was
performed using tail clips and genomic PCR. Experiments using multiple
transgenic mice used age- and sex-matched mice. Unless otherwise stated
transgenic mice were on the C57BL6 genetic background.
In Vivo Endotoxin Shock Models. Mice were injected i.p. with differing
amounts of LPS and/or zVAD as described in the text. Body temperature was
monitored to assess animal health, and mice were killed at established hu-
mane endpoints (body temperature less than 27 °C). After mice were killed,
peritoneal lavage was performed with 10 mL of cold PBS, and blood was
drawn via cardiac puncture.
Generation of Macrophages and Mouse Embryonic Fibroblasts. Mouse bone
marrow was differentiated for 7 d using macrophage colony-stimulating factor
to generatemacrophage cells. Primarymouse embryonic fibroblasts were prepared
by standard procedures (50) and immortalized by E1A/Ras transformation (51).
In Vitro Cell Stimulations and Microscopy. Macrophages were treated with
various PAMPs such as LPS (100 ng/mL) or poly I:C (20 μg/mL) or with cytokines
such as TNF-α (50 ng/mL) or IFN-β (25 ng/mL) in the absence or presence of
zVAD (25 or 50 μM). Cell death was quantitated at various time intervals
after treatment.
For cell imaging, macrophages were plated in a 96-well flat-bottom plate
at 7 × 104 cells per well 24 h before the addition of inhibitors and agonists.
Cells were treated with corresponding reagents for 24 h, stained with
Hoechst (2.5 μg/mL; Invitrogen, 33342) and propidium iodide (1:10 dilution;
BD Pharmingen, 550825), and incubated at 37 °C for 25 min before being
examined by immunofluorescence microscopy using a Zeiss AxioObserver.D1
microscope. The AxioVision Rel. 4.8 program was used to analyze images.
Cells were quantitated using the Lumenera Infinity Analyze program.
In Vitro Inhibitor Assays. Macrophages were treated with a variety of small
molecule inhibitors over the course of experiments as described in the text.
Inhibitors used were as follows: z-VAD-FMK (EMD Millipore, 627610), LPS
from E. coli 055:B5 (Sigma, L4005), Necrostatin-1 (Sigma, 9037), TNF-α (R&D
Systems, 410-MT), mouse IFN-β (PBL InferonSource, Life Technologies, 12400-1),
and polyI:C (Sigma-Aldrich, P1530). A variety of techniques were used for
experiments; details are given in the text. In general, macrophages were
given 24 h to adhere to the plates before treatment with inhibitors was
initiated. After treatment with appropriate concentrations of inhibitors,
cells were left for 24 h before cell death or viability was assessed, unless
otherwise stated in the text. In experiments that used LPS stimulation,
a concentration of 100 ng/mL was used consistently. Experiments to gener-
ate protein lysates from cells were performed with 250,000 cells per well in
24-well plates and were terminated at various time points.
Viability Assays (MTT Assay). Cell viability was assessed using the 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay. MTT
staining reagent was added to cells at a final concentration of 0.5 mg/mL and
incubated at 37 °C for 2 h. Then cells were lysed, and the MTT crystals were
solubilized using 5 mM HCl in isopropyl alcohol. Results were quantified by
measuring absorption at 570 nm with a reference wavelength of 650 nm on
a Molecular Devices Emax plate reader. Viability measurements were nor-
malized to the similarly stimulated control (i.e., LPS+zVAD normalized to LPS
alone of the same genotype) unless otherwise described. Cell death also was
assessed using a commercial lactate dehydrogenase release assay (Sigma-
Aldrich, TOX7) according to the manufacturer’s instructions.
Western Blotting. Cell lysates were obtained during various experiments by
lysing cells directly in 1% SDS lysis buffer with 1% β-mercaptoethanol and
boiling immediately to minimize protein degradation. (Note: We have
found the phosphorylated forms of Rip1 and Rip3 are highly sensitive to the
lysis buffer and protocol used.) Western blot analysis was performed
by standard protocol. Antibodies used were as follows: mouse anti-Rip1
(BD, 610458), mouse anti-Rip3 (ProSci Inc., 2283), mouse anti-actin (BD, 612656),
rabbit anti-STAT1 (Cell Signaling, 9172), rabbit anti-pSTAT1 (Cell Signaling,
9167), rabbit anti-STAT2 (Cell Signaling, 4597), and rat anti-MLKL mono-
clonal (EMD Millipore, MABC604). We confirmed the specificity of the Rip3
antibody used here by the absence of Rip3 signal in the Rip3-deficient
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macrophages (Fig. S6). Our recent work with recombinant Rip1 also confirms
the specificity of the Rip1 antibody used here (52).
FACS Cell Staining. Peritoneal cells were stained with antibodies against
CD11b and F4/80 followed by staining with propidium iodide and were
evaluated on a BD FACSCanto II Flow cytometer.
Cytokine Array. Serum cytokines were screened using the Multi-Analyte ELI-
SArray Kit (SABiosciences, MEM-004A) according to the manufacturer’s instruc-
tions. The absorbance values were read at 450 nm on a FilterMax F5 Multimode
microplate reader (Molecular Devices). Wavelength correction was done by
subtracting the readings at 570 nm. Cytokine concentrations were calculated in
picograms per milliliter based on the OD values obtained for the standards.
Quantitative RT-PCR. Total RNA was isolated using TRIzol reagent (Life
Technologies). Isolated RNA was reverse transcribed into cDNA in a 20-μL
reaction volume using SuperScript III Reverse Transcriptase (Invitrogen,18080–
044) as follows: 1 μg of RNA template was added to 0.5 μL of oligo(dT)
(50 μM), 0.5 μL of random primers (50–250 ng), 4 μL of 5× First Strand
buffer, 1 μL of DTT (0.1 M), 1 μL of dNTP (10 mM), 1 μL of RNase OUT (40
units/μL), and 1 μL of SuperScript III (200 units/μL). After cDNA synthesis,
2 μL of cDNA was analyzed using the SYBR Green (Life Technologies) fast
method performed on an Applied Biosystems 7500 quantitative RT-PCR
system. The primers used were as follows: Actin (forward) 5′-GATCAA-
GATCATTGCTCCTCCTG-3′, (reverse) 5′-AGGGTGTAAAACGCAGCTCA-3′; IRF-9
(forward) 5′-AGCAACTG CAACTCTGAGCTA-3′, (reverse) 5′-ACTCGGC CAC-
CATA GATGAAG-3′.
Statistical Analyses. All graphs show the average result taken from at least
three experiments, each performed in triplicate. Error bars show the SEM.
Significance was determined by Student’s t test using the GraphPad Prism
software package.
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